EDIT Editas Medicine Inc

$EDIT The most crucial insight discussed yesterday at Mesa was that companies could accelerate their proprietary platform mechanisms by leveraging the FDA data pool. While Intellia is taking this platform success to a commercial scale, Editas has reminded investors just how valuable its proprietary AsCas12a platform could become in the future. Editas is not merely a laboratory developing its own drug (EDIT-401); it is also the ultimate patent powerhouse of the biotechnology world—a gatekeeper whose door must be knocked on, and to whom a "transit fee" must be paid, by any major corporation (such as Vertex, BMS, Novartis, etc.) wishing to enter the gene therapy market.

$EDIT As someone who’s already on cholesterol MEDS? This is very important for me and I’m rooting for this Company’s success ! I Even tipped my toe into the water and picked up a few shares earlier in the day to set and forget. 

$EDIT If EDIT-401 ever becomes a success we will all be millionaires, at least those who bought enough shares at these ridiculously low prices.

$EDIT Hey & David Ricks, let's talk strategic math. You bought Verve for $1.3B to rule the CRISPR cardio market with a ~60% efficacy. Good move. But ignoring Editas Medicine ($EDIT) is a fatal mistake. EDIT-401 uses next-gen Cas12a—it’s direct, more precise, and delivers a massive 90% efficacy in primates. It is a scientifically superior asset. Dosing in humans is clearing now. If Editas goes to a rival, your $1.3B Verve investment will look like yesterday's news, and you’ll lose the entire cardiovascular market share. $EDIT is heavily mispriced right now, but its fair value floor is at least $5.00 today. Buy Editas for $1.5B before November 8th. Consolidate the IP, lock down the monopoly, and end the debate. Clock is ticking. ⏳ #CRISPR #Cardio #Biotech #M&A EDIT LLY

$EDIT İf you wake up october 7 morning and see this ?Eli Lilly is acquiring the gene editing company Editas Medicine. Under the terms of the agreement, Editas shareholders will receive an upfront cash payment of $3.65 per share. With the activation of additional contingent value rights (CVRs) tied to clinical successes, the total acquisition price will reach $5.65 per share. Not financel advice

$EDIT possibly thawing as Biotech AI data strategies heats up. $EDIT's proprietary training data and methodology along with their data set could offer compressed discovery time and a possible catalyst for perceived value growth.

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027 $EDIT $XBI https://stocktwits.com/news/equity/markets/editas-medicine-gets-clearance-for-first-human-trial-of-gene-editing-drug/cZDUoyRRBND

$EDIT Results may speak. Reni worked but was economically not feasible. In-Vivo treatment for cardiovascular diseases is very much viable. Current treatment alternatives is taking pills every year. Both have their place but only editing is long term. Prohibition pills are temporary.

$EDIT it‘s like a lot of other AI potentials…truth lies into the details and most people don‘t understand the details. Detecting possible matches of Enzymes and proteins is just a minor step on the way to create a working medicine….so many other things have to be done where AI‘s help is limited…

$EDIT whole sector dropping because of a hot air AI company advertisement . Who will inject CRISPER SLOP edits?

$EDIT Just look at the graph for the last 6 months. It is obvious that we have been victim of some big fish. This stock went up and down and up again between $ 2.50 and 3.70. NOw we are again starting our climb to > 3.70...this could go very very fast. 20% in a couple of weeks: imagine

$EDIT "net loss of $18.2 million, or $0.15 per share, compared with a $53.2 million loss a year earlier" K-8

$EDIT no more games guys we all know the drill we go to 3 than back to 2.6 and repeat 1 billion times

$EDIT for the CRISPR companies this is actually great news because their first step in detecting possible drug candidates is much enhanced and overall drug development process therefore shorter and less expensive. This actually should bring the share price up not down...

$EDIT this stock is going to breakout soon 🚀there is so much volatility in the world right now any good news is going to cause a face ripping ralley stay invested dont get priced out 📈🐂

$EDIT Guggenheim upgraded Editas Medicine to Buy from Neutral with a $5 price target [er the fly, one to eye this morning

$EDIT This is relatively low risk, high reward at these prices. They hit, stock hits. Bottom line. 💉🧬

$EDIT is showing unusual volume activity that could signal a big move! $MI #momentum $FRGT #stockstotrade $AIXI #darkpoolai

$EDIT I’d be displeased. They’ve set this up to potentially unlock much higher valuation if the trial goes well.

$EDIT SLS is at the forefront of extending lives for cancer patients and next press release is expected to skyrocket the stock by 100%s.